Our vision is to make cutting-edge therapies accessible to Indian patients

Amit Mookim, CEO, Immuneel Therapeutics, discusses the launch of Qartemi, India's first CAR T-cell therapy, and the company's vision to make advanced cell and gene therapies accessible and affordable for Indian patients.

- 

He also shares insights on Immuneel's growth strategies, partnerships, and plans to position India as a global hub for innovative cancer treatments, in an interview with Lakshmipriya Nair

Immuneel recently launched Qartemi in India. How does its launch align with Immuneel's broader vision for cell and gene therapies? The launch of Qartemi, our CAR T-cell therapy for Non-Hodgkin's Lymphoma, marks a pivotal moment in our journey to provide access to advanced cell and gene therapies in India. Our vision is to make cutting-edge therapies accessible to Indian patients without compromising on global quality and standards. Qartemi is a testament to this vision, it's not just a product, but a paradigm shift in how we approach cancer care. By bringing Qartemi to the Indian market, we're not only providing renewed hope to patients but also paving the way for India to become a hub for affordable, innovative therapies in the global cell and gene therapy landscape.

What are Immuneel Therapeutics' immediate and long-term growth strategies to expand its portfolio and reach within India and globally? Our immediate focus is on scaling access to Qartemi by establishing robust partnerships with leading hospitals and healthcare providers across India. We are also focusing on creating awareness, training physicians and the various stakeholders at the hospital/infusion site, educating patients and caregivers about CAR T-cell therapy.